





Docket No.: 20342/1202653-US3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Beth BURNSIDE et al.

Application No.: 10/758,417

Confirmation No.: 5644

Filed: January 16, 2004

Art Unit: 1617

For: ORAL PULSED DOSE DRUG DELIVERY  
SYSTEM

Examiner: Shengjun WANG

**SECOND PRELIMINARY AMENDMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTION**

A substitute specification under 37 C.F.R. 1.125 is filed concurrently with this Second Preliminary Amendment. The instant application is a continuation of U.S. Patent Application Serial No. 10/172,705 (abandoned), which is a continuation of U.S. Patent Application Serial No. 09/807,462 (now U.S. Patent No. 6,605,300). The contents of the '462 application are incorporated by reference into the instant application (*see* specification as filed, first paragraph). Inadvertently, the specification as filed did not include the entire contents of the '462 specification. The substitute specification corrects this inadvertent mistake.

A marked-up copy and a clean copy of the substitute specification are provided pursuant to 37 C.F.R. §§ 1.121(b)(3) and 1.125. Line numbers have been added to the substitute specification to facilitate locating passages. The page and line numbers listed in this amendment refer to the marked-up substitute specification unless otherwise specified.

A Supplementary Information Disclosure Statement is filed concurrently herewith providing a copy of an Amendment after Final Rejection, filed April 21, 2003 in the '462 application, which is cited herein.

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows.

**Amendments to the specification** begin on page 3 of this paper.

**A Listing of the claims** begins on page 4 of this paper.

**Remarks** begin on page 16 of this paper.